

Brand Name: Duaklir Genuair

Generic: aclidinium/formoterol


Type: small molecule

Year Accepted/Phase: 2019

Mechanism:

Aclidinium is a muscarinic receptor antagonist that blocks the action of acetylcholine, leading to bronchodilation. Formoterol is a long-acting beta2-agonist that relaxes the muscles in the airways, making breathing easier.

Chemical Structure:



Indication:

Duaklir Genuair is indicated for the maintenance treatment of COPD, including chronic bronchitis and emphysema.

Clinical trials:

Clinical Trials for COPD

Pubmed: <https://pubmed.ncbi.nlm.nih.gov/27621610/>

Purpose: Evaluate the efficacy and safety of aclidinium/formoterol in patients with COPD.

Dates: Clinical trials for Duaklir Genuair were conducted in the 2010s.

Results: These trials demonstrated that the combination of aclidinium/formoterol provided superior bronchodilation compared to either component alone. It also improved lung function, symptoms, and quality of life in patients with COPD.

Impact: The positive results from these trials supported the approval of Duaklir Genuair for the maintenance treatment of COPD.